The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease.
about
Effectiveness of group music intervention against agitated behavior in elderly persons with dementia.Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer's disease dementia.Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept).Is there a neuropathology difference between mild cognitive impairment and dementia?Pathology and pathways of Alzheimer's disease with an update on new developments in treatment.Calpain dysregulation in Alzheimer's diseaseLooking backward to move forward: early detection of neurodegenerative disorders.Advances in the early detection of Alzheimer's disease.Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's diseaseImaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders.The place of choline acetyltransferase activity measurement in the "cholinergic hypothesis" of neurodegenerative diseases.Atrophy of the cholinergic Basal forebrain over the adult age range and in early stages of Alzheimer's disease.Protecting the synapse: evidence for a rational strategy to treat HIV-1 associated neurologic disease.Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme.Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability.Blueberry opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activation protein kinaseNeuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders.The cholinergic system and Parkinson disease.Cholinergic dysfunction in Parkinson's disease.Enhanced mossy fiber sprouting and synapse formation in organotypic hippocampal cultures following transient domoic acid excitotoxicity.Cholinergic involvement and synaptic dynamin 1 expression in Yokukansan-mediated improvement of spatial memory in a rat model of early Alzheimer's disease.Beta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons.The reliability, validity, sensitivity, specificity and predictive values of the Chinese version of the Rowland Universal Dementia Assessment Scale.Beta-amyloid-induced dynamin 1 depletion in hippocampal neurons. A potential mechanism for early cognitive decline in Alzheimer disease.Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease.High levels of synaptosomal Na(+)-Ca(2+) exchangers (NCX1, NCX2, NCX3) co-localized with amyloid-beta in human cerebral cortex affected by Alzheimer's disease.Dynamin 1 depletion and memory deficits in rats treated with Abeta and cerebral ischemia.A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease.Reversal of visual attention dysfunction after AMPA lesions of the nucleus basalis magnocellularis (NBM) by the cholinesterase inhibitor donepezil and by a 5-HT1A receptor antagonist WAY 100635.Increased anticholinergic challenge-induced memory impairment associated with the APOE-epsilon4 allele in the elderly: a controlled pilot study.A cross-sectional study on cerebrospinal fluid biomarker levels in cognitively normal elderly subjects with or without a family history of Alzheimer's disease.Atorvastatin Prevents Cognitive Deficits Induced by Intracerebroventricular Amyloid-β1-40 Administration in Mice: Involvement of Glutamatergic and Antioxidant Systems.ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures.Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.Alzheimer's Disease: The Alternative Serotonergic Hypothesis of Cognitive Decline.Association of Neuropathological Markers in the Parietal Cortex With Antemortem Cognitive Function in Persons With Mild Cognitive Impairment and Alzheimer Disease.Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study.Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.Challenging assumptions about Alzheimer's disease: mild cognitive impairment and the cholinergic hypothesis.
P2860
Q30392074-067EADFF-48CE-42F4-B545-9B44067FC424Q34364216-C6D0CAF8-6A0D-495D-9899-F357E23CA7B5Q34732823-C9E6DDEC-A2FB-4361-ACA8-CBEDDFBEC863Q34776816-3F3D1713-68D7-4F44-ADB7-85558A58D6AFQ35151999-63AAAEE0-9DF7-40F5-86FF-ED634478CC1AQ35361462-549377DB-8480-4F55-8043-C30816C72C4DQ35573431-02C0A97D-4E4F-496A-AC48-B70D57091077Q35857470-50B41CD2-28A6-46C4-A2AE-32252BC8994DQ35863422-D408B95C-D633-43E7-8756-AF2CC9C9F4F4Q35995627-1BA0C97B-56E7-41FA-81A8-DB32D9D726A8Q36743706-02AA919B-E695-48CB-B68F-1DBF9AF8B212Q36973492-C266207B-100A-4EEB-852A-34C85DC957ECQ36981538-F6999CAC-8515-46E4-A205-BA6D22E0778EQ37015379-C603D6FE-73A3-40F6-9556-9200A8338F4EQ37130148-2D858052-2A0D-4D0F-8E97-9DB6E392EED5Q37326829-5CABD5D8-14FE-46BF-A722-A85C780DFFF4Q37362513-20FFFD44-65DC-4776-836E-6C986AAB7C8AQ37473457-3BC8E621-1CEB-42E2-A64A-83425B9004FAQ37671065-CD3A77AA-DF1E-415B-A1CC-0BA4AF05EA46Q37709932-B221A8A3-E790-4824-BB27-6BF28F7E2450Q39292803-1628192B-50CD-467D-BD3A-EBBB37D4D07BQ39570243-199E08CD-025E-4E1F-9E20-5F5FC593D22FQ41437626-6147650E-2125-4FF5-886A-AD188B1BBFCDQ41497099-67D2E78C-84E5-42EC-9CC1-66FB84708244Q42274064-4AA5A92A-0DED-47E3-8303-026D93CAE576Q42515808-1B4920E3-2E24-453E-AB3F-A3ECF02716D3Q42723718-45D03418-B3FB-442C-A218-EBD4C9C82170Q43176019-2C5D62F3-203E-448E-AD21-F2D7B7E651DDQ43272692-23DF2F79-51BC-48AB-A5FC-1512228C07EAQ44347231-4685850B-A651-49FD-897E-38A1C3D51039Q44736078-063902F7-CEFD-4622-B3EF-9E63549777F4Q46142593-0702EDC4-54D2-4DDA-BCDA-1E2722A0207EQ48253206-A6758894-9ED6-40EC-B3B7-A6CDB1BD95CFQ48530200-290CE32F-A556-4EFC-995B-200DD1987AF4Q49256155-2779EC52-F22A-4A19-9023-D31703459C95Q49562614-3D7ACA1C-B8DA-4061-923E-BB8CC23EE50EQ51154144-5B0DCAD9-0921-4413-BAC6-EBCD3057400DQ51903177-07A7CFA9-A5A7-4F2D-9EB0-D6CD895BC6B9Q51933837-1617FA20-7F9B-455F-AAB3-3D1776A845B1Q53350820-9985BC35-13EB-4C8D-BB34-CBF8E221E51F
P2860
The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease.
@en
The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease.
@nl
type
label
The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease.
@en
The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease.
@nl
prefLabel
The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease.
@en
The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease.
@nl
P2093
P356
P1433
P1476
The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease.
@en
P2093
P304
P356
10.1212/WNL.55.9.1278
P407
P577
2000-11-01T00:00:00Z